Lexaria Bioscience (LEXX) Debt to Equity (2011 - 2022)

Lexaria Bioscience has disclosed Debt to Equity across 12 years of filings, most recently posting $0.0 for Q2 2022.

• Debt to Equity for Q2 2022 came in at $0.0, up 587.8% year-over-year; the trailing twelve-month figure through May 2022 was $0.0 (up 587.8% YoY), and the FY2021 annual result was $0.0, down 95.09% from the prior year.
• Debt to Equity came in at $0.0 for Q2 2022 at Lexaria Bioscience, up from $0.0 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.06 in Q4 2020 to a low of $0.0 in Q2 2021.
• The 5-year median for Debt to Equity is $0.0 (2018), against an average of $0.01.
• Across the five-year window, Debt to Equity tumbled 99.65% in 2018 and soared 2023.81% in 2021, its largest moves.
• Lexaria Bioscience's Debt to Equity stood at $0.01 in 2018, then soared by 124.29% to $0.01 in 2019, then surged by 355.67% to $0.06 in 2020, then slumped by 98.95% to $0.0 in 2021, then surged by 30.14% to $0.0 in 2022.
• The last three Debt to Equity figures came in at $0.0 (Q2 2022), $0.0 (Q4 2021), and $0.0 (Q3 2021), per Business Quant data.